Literature DB >> 263717

Metabolism and excretion of 3H-1,25-(OH)2-vitamin D3 in healthy adults.

R W Gray, A E Caldas, D R Wilz, J Lemann, G A Smith, H F DeLuca.   

Abstract

The synthesis of very high specific activity 25-OH-vitamin D3 (78 Ci/mmol) has made possible the study of the metabolism and plasma disappearance of 3H after a single dose of 3H-1,25-(OH)2-D3 in quantities that are only 10-20% of the endogenous plasma pool. We studied seven healthy adults who were given doses of 1,25-(OH)2-D3 ranging from 30-2300 pmol. Plasma disappearance was rapid with only 14 +/- 2% of administered 3H remaining in the plasma pool 4 h after labeling. Plasma metabolite profiles during the first 4 h showed only 1,25-(OH)2-D3. Thereafter, significant amounts of other metabolites were detected. The 6-day cumulative excretion of 3H in urine and feces (virtually all associated with metabolites of 1,25-(OH)2-D3) averaged 16 +/- 3% and 49 +/- 11% of the dose, respectively. Compartmental analysis of the isotope data for two subjects who received the smallest doses of 1,25-(OH)2-D3 indicated that endogenous renal 1,25-(OH)2-D3 synthesis rates approximate 0.8-2.4 nmol/day (0.3-1.0 microgram/day).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 263717     DOI: 10.1210/jcem-46-5-756

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

Review 2.  Vitamin D and the kidney.

Authors:  Rajiv Kumar; Peter J Tebben; James R Thompson
Journal:  Arch Biochem Biophys       Date:  2012-03-15       Impact factor: 4.013

Review 3.  Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis.

Authors:  Wei Zhen Yeh; Melissa Gresle; Vilija Jokubaitis; Jim Stankovich; Anneke van der Walt; Helmut Butzkueven
Journal:  Br J Pharmacol       Date:  2020-08-05       Impact factor: 8.739

4.  1,25 dihydroxyvitamin D-induced inhibition of 3H-25 hydroxyvitamin D production by the rachitic rat liver in vitro.

Authors:  D T Baran; M L Milne
Journal:  Calcif Tissue Int       Date:  1983-07       Impact factor: 4.333

5.  1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis.

Authors:  J C Gallagher; C M Jerpbak; W S Jee; K A Johnson; H F DeLuca; B L Riggs
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  The influence of dihydroxylated vitamin D metabolites on bone formation in the chick.

Authors:  I R Dickson; A K Hall; S S Jande
Journal:  Calcif Tissue Int       Date:  1984-01       Impact factor: 4.333

7.  25-Hydroxycholecalciferol in experimental osteoporosis.

Authors:  M Carrozzo; R Pallante; F P Cantatore; F Lo Sasso; M D'Amore; V Pipitone
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

Review 8.  Hyperphosphatemia of chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund; Ping Qiu; Raymond Pratt
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

Review 9.  Interplay between vitamin D and the drug metabolizing enzyme CYP3A4.

Authors:  Zhican Wang; Erin G Schuetz; Yang Xu; Kenneth E Thummel
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-15       Impact factor: 4.292

10.  Biliary excretion of radioactivity after intravenous administration of 3H-1,25-dihydroxyvitamin D3 in man.

Authors:  J E Ledger; G J Watson; C C Ainley; J E Compston
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.